2193-6382

Infectious Diseases and Therapy

Springer-Verlag

View prefix report (10.1007)

Health Score

0 Good

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Add abstracts to 1370 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

High impact1370 DOIs
2

Attach ORCID iDs across 567 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

Medium impact567 DOIs
3

Add license metadata to 180 records

License metadata tells indexers and readers how each article may be reused.

Low impact180 DOIs

DOIs for this ISSN

Showing the top 5 of 1383 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 Infections in Cancer Patients with Solid Tumors: A Review (10.1007/s40121-017-0146-1)
Abstract ORCID License
183.54 279
2 Defining the Epidemiology and Burden of Severe Respiratory S… (10.1007/s40121-016-0123-0)
Abstract ORCID License
179.85 249
3 The Burden and Long-term Respiratory Morbidity Associated wi… (10.1007/s40121-017-0151-4)
Abstract ORCID License
171.25 191
4 Rapid and Effective Virucidal Activity of Povidone-Iodine Pr… (10.1007/s40121-015-0091-9)
Abstract ORCID License
169.33 180
5 Who Is the Patient at Risk of CMV Recurrence: A Review of th… (10.1007/s40121-017-0180-z)
Abstract ORCID License
161.19 140
6 Recurrent Lower Urinary Tract Infections Have a Detrimental… (10.1007/s40121-014-0054-6)
Abstract ORCID License
155.11 116
7 A Review of the Evidence for Using Bedaquiline (TMC207) to T… (10.1007/s40121-013-0009-3)
Abstract ORCID License
150.96 102
8 Dalbavancin: A Novel Lipoglycopeptide Antibiotic with Extend… (10.1007/s40121-015-0077-7)
Abstract ORCID License
148.67 95
9 Minocycline for the Treatment of Multidrug and Extensively D… (10.1007/s40121-017-0153-2)
Abstract ORCID License
146.93 90
10 Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatm… (10.1007/s40121-016-0103-4)
Abstract ORCID License
145.46 86
11 Meningococcal Vaccinations (10.1007/s40121-016-0107-0)
Abstract ORCID License
145.46 86
12 Defining the Risk and Associated Morbidity and Mortality of… (10.1007/s40121-016-0130-1)
Abstract ORCID License
145.09 85
13 Observation of “Seesaw Effect” with Vancomycin, Teicoplanin,… (10.1007/s40121-014-0023-0)
Abstract ORCID License
144.32 83
14 Safety and Effectiveness of Palivizumab in Children at High… (10.1007/s40121-014-0046-6)
Abstract ORCID License
143.93 82
15 Dolutegravir, the Second-Generation of Integrase Strand Tran… (10.1007/s40121-014-0029-7)
Abstract ORCID License
140.63 74
16 Defining the Incidence and Associated Morbidity and Mortalit… (10.1007/s40121-017-0160-3)
Abstract ORCID License
139.75 72
17 Adverse Events Associated with Fosfomycin Use: Review of the… (10.1007/s40121-015-0092-8)
Abstract ORCID License
138.84 70
18 Epidemiology and Risk Factors for Community-Associated Clost… (10.1007/s40121-016-0117-y)
Abstract ORCID License
138.84 70
19 Antimicrobial Stewardship from Policy to Practice: Experienc… (10.1007/s40121-015-0080-z)
Abstract ORCID License
137.91 68
20 Antimicrobial Resistance of Escherichia coli Causing Uncompl… (10.1007/s40121-015-0095-5)
Abstract ORCID License
137.91 68
21 Defining the Risk and Associated Morbidity and Mortality of… (10.1007/s40121-016-0142-x)
Abstract ORCID License
137.91 68
22 Tedizolid Phosphate: a Next-Generation Oxazolidinone (10.1007/s40121-015-0060-3)
Abstract ORCID License
135.97 64
23 Challenges and Solution of Invasive Aspergillosis in Non-neu… (10.1007/s40121-017-0183-9)
Abstract ORCID License
134.95 62
24 Impact of a Multidisciplinary Culture Follow-up Program of A… (10.1007/s40121-014-0026-x)
Abstract ORCID License
132.81 58
25 Real-World Experience with Oritavancin Therapy in Invasive G… (10.1007/s40121-017-0156-z)
Abstract ORCID License
132.26 57
26 Defining the Risk and Associated Morbidity and Mortality of… (10.1007/s40121-016-0137-7)
Abstract ORCID License
131.69 56
27 Effect and Safety of Meropenem–Vaborbactam versus Best-Avail… (10.1007/s40121-018-0214-1)
Abstract ORCID
130.64 409
28 Antimicrobial Stewardship with Pharmacist Intervention Impro… (10.1007/s40121-015-0082-x)
Abstract ORCID License
128.70 51
29 Antibiotic Discontinuation Rates Associated with Positive Re… (10.1007/s40121-015-0087-5)
Abstract ORCID License
127.42 49
30 Single-Tablet Regimens in HIV Therapy (10.1007/s40121-014-0024-z)
Abstract ORCID License
126.76 48
31 Molecular Characterization of Invasive Carbapenem-Resistant… (10.1007/s40121-016-0125-y)
Abstract ORCID License
126.76 48
32 A Systematic Review of the Clinical Utility of Cycle Thresho… (10.1007/s40121-020-00324-3)
Abstract ORCID
126.19 333
33 A Review of HIV Pre-Exposure Prophylaxis: The Female Perspec… (10.1007/s40121-017-0159-9)
Abstract ORCID License
125.41 46
34 Hypoxia-Inducible Factor (HIF) as a Pharmacological Target f… (10.1007/s40121-014-0030-1)
Abstract ORCID License
124.71 45
35 A Retrospective Review of the Clinical Experience of Linezol… (10.1007/s40121-014-0032-z)
Abstract ORCID License
124.71 45
36 Evaluation of High-Dose Daptomycin Versus Vancomycin Alone o… (10.1007/s40121-014-0055-5)
Abstract ORCID License
124.71 45
37 Considerations About Antimicrobial Stewardship in Settings w… (10.1007/s40121-015-0081-y)
Abstract ORCID License
123.99 44
38 Clostridium difficile Infection in Special High-Risk Populat… (10.1007/s40121-016-0124-z)
Abstract ORCID License
123.99 44
39 The Safety and Economic Impact of Cefazolin versus Nafcillin… (10.1007/s40121-017-0148-z)
Abstract ORCID License
123.26 43
40 Antimicrobial Stewardship in the Emergency Department (10.1007/s40121-015-0084-8)
Abstract ORCID License
122.51 42
41 In Vitro Bactericidal and Virucidal Efficacy of Povidone-Iod… (10.1007/s40121-018-0200-7)
Abstract ORCID
122.51 281
42 Climate Change and Cascading Risks from Infectious Disease (10.1007/s40121-022-00647-3)
Abstract ORCID
121.73 271
43 Tigecycline for the Treatment of Severe and Severe Complicat… (10.1007/s40121-014-0050-x)
Abstract ORCID License
120.96 40
44 Antimicrobial Stewardship in Australian Hospitals and Other… (10.1007/s40121-015-0083-9)
Abstract ORCID License
120.15 39
45 Assessments of Opportunities to Improve Antibiotic Prescribi… (10.1007/s40121-017-0175-9)
Abstract ORCID License
118.48 37
46 Incidence and Predisposing Factors of Vancomycin-Induced Nep… (10.1007/s40121-013-0004-8)
Abstract ORCID License
117.62 36
47 Chikungunya in the Caribbean: An Epidemic in the Making (10.1007/s40121-014-0043-9)
Abstract ORCID License
117.62 36
48 Current Microbiology of Surgical Site Infections in Patients… (10.1007/s40121-014-0048-4)
Abstract ORCID License
116.72 35
49 Tenofovir: What We Have Learnt After 7.5 Million Person-Year… (10.1007/s40121-015-0070-1)
Abstract ORCID License
116.72 35
50 Ebola Virus Infection: Overview and Update on Prevention and… (10.1007/s40121-015-0079-5)
Abstract ORCID License
116.72 35